An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Figure 4. High-throughput screening at 10 mM for WBZ_4 (red) and imatinib (STI_571; blue; control) over a battery of 228 human kinases displayed in a T7-bacteriophage library (Ambit Biosciences).. From: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
CitationFull text
Figure 2. Comparison of de-wetting propensities of C-Kit and JNK.. From: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Figure 3. Water exclusion patterns promoted by imatinib and WBZ_4 on the primary target C-Kit.. From: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Figure 8. Higher specificity of WBZ_4 compared with imatinib as assayed through Western blots.. From: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Figure 5. Kinetic inhibitory impact of compounds WBZ_4 and imatinib determined by measuring phosphorylation rates through spectrophotometric assays of C-Kit and Bcr-Abl kinase activity.. From: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Figure 9. Xenograft models of anticancer activity.. From: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Figure 6. In vitro comparison of inhibitory impact of imatinib and WBZ_4 on Abl and C-Kit kinase.. From: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Figure 1. Comparison of de-wetting propensities of major imatinib targets and drug redesign dictated by de-wetting differences.. From: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Figure 7. Comparison of inhibitory impact of imatinib and WBZ_4 on cell proliferation.. From: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Figure 10. In vivo assays for cardiotoxicity of imatinib and WBZ_4.. From: An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on